CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Androgen-receptor (AR) inhibitors, including enzalutamide, are used for treatment of all metastatic castration-resistant prostate cancers (mCRPCs). However, some patients develop resistance or never respond. We find that the transcription factor CREB5 confers enzalutamide resistance in an open reading frame (ORF) expression screen and in tumor xenografts. CREB5 overexpression is essential for an enzalutamide-resistant patient-derived organoid. In AR-expressing prostate cancer cells, CREB5 interactions enhance AR activity at a subset of promoters and enhancers upon enzalutamide treatment, including MYC and genes involved in the cell cycle. In mCRPC, we found recurrent amplification and overexpression of CREB5. Our observations identify CREB5 as one mechanism that drives resistance to AR antagonists in prostate cancers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Leek, J. T., Johnson, W. E., Parker, H. S., Jaffe, A. E., & Storey, J. D. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts034 · Cited by 6,231 · cited 1×
“, 2007) via the R Bioconductor package “sva” (Leek et al., 2012), version V3.”
MethodIncreased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
Scher, H. I., Fizazi, K., Saad, F., Taplin, M.-E., Sternberg, C. N., Miller, K., de Wit, R., Mulders, P., Chi, K. N., Shore, N. D., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1207506 · Cited by 4,586
Fagerberg, L., Hallström, B. M., Oksvold, P., Kampf, C., Djureinovic, D., Odeberg, J., Habuka, M., Tahmasebpoor, S., Danielsson, A., Edlund, K., et al. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.035600 · Cited by 3,665
Integrative Clinical Genomics of Advanced Prostate Cancer
Robinson, D., Van Allen, E. M., Wu, Y.-M., Schultz, N., Lonigro, R. J., Mosquera, J.-M., Montgomery, B., Taplin, M.-E., Pritchard, C. C., Attard, G., et al. (2015) · Cell · doi:10.1016/j.cell.2015.05.001 · Cited by 3,645
Self-citationATAC-seq: a method for assaying chromatin accessibility genome-wide
Buenrostro, J. D., Wu, B., Chang, H. Y., & Greenleaf, W. J. (2015) · Current Protocols in Molecular Biology · doi:10.1002/0471142727.mb2129s109 · Cited by 3,289
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 3×
“Mutations of Wnt signaling regulators, including ones that perturb function of the tumor suppressor gene APC or activate CTNNB1 or the Wnt signal enhancer RSPO2, have been found in mCRPC patients (Grasso et al., 2012; Gundem et al., 2015; Robinson et al., 2015).”
BackgroundEmerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer
Watson, P. A., Arora, V. K., & Sawyers, C. L. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4016 · Cited by 1,536 · cited 4×
“However, some patients never respond to hormonal therapies, and nearly all patients ultimately develop resistance to all AR-targeted agents (Watson et al., 2015; Bubley and Balk, 2017).”
BackgroundInfluentialAndrogen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling
Bluemn, E. G., Coleman, I. M., Lucas, J. M., Coleman, R. T., Hernandez-Lopez, S., Tharakan, R., Bianchi-Frias, D., Dumpit, R. F., Kaipainen, A., Corella, A. N., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.003 · Cited by 744 · cited 6×
“Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.”
BackgroundInfluentialAttard, G., Reid, A. H. M., A'Hern, R., Parker, C., Oommen, N. B., Folkerd, E., Messiou, C., Molife, L. R., Maier, G., Thompson, E., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.0642 · Cited by 605
A public genome-scale lentiviral expression library of human ORFs
Yang, X., Boehm, J. S., Yang, X., Salehi-Ashtiani, K., Hao, T., Shen, Y., Lubonja, R., Thomas, S. R., Alkan, O., Bhimdi, T., et al. (2011) · Nature Methods · doi:10.1038/nmeth.1638 · Cited by 570 · cited 16×
“(C) Of the 17,255 ORFs, Z scores are displayed for experiments in the CSS (x axis) and CSS + enzalutamide (y axis) treatment arms.”
BackgroundMethodInfluentialSelf-citationTarget analysis by integration of transcriptome and ChIP-seq data with BETA
Wang, S., Sun, H., Ma, J., Zang, C., Wang, C., Wang, J., Tang, Q., Meyer, C. A., Zhang, Y., & Liu, X. S. (2013) · Nature Protocols · doi:10.1038/nprot.2013.150 · Cited by 544 · cited 5×
“Upon identifying differentially expressed transcripts in CREB5-overexpressing cells posttreatment, we used binding and transcription analysis (BETA) (Wang et al., 2013) to computationally integrate the ChIP-seq with the RNA-seq data to globally determine CREB5/AR direct target genes and the regulatory enhancer, promot…”
MethodInfluentialThe androgen receptor cistrome is extensively reprogrammed in human prostate tumorigenesis
Pomerantz, M. M., Li, F., Takeda, D. Y., Lenci, R., Chonkar, A., Chabot, M., Cejas, P., Vazquez, F., Cook, J., Shivdasani, R. A., et al. (2015) · Nature Genetics · doi:10.1038/ng.3419 · Cited by 470 · cited 4×
“, 2011) to examine interactions at critical binding sites (TMPRSS2, KLK3, STK39) for all ChIP-seq experiments compared to previous studies (Pomerantz et al., 2015).”
BackgroundResultInfluentialSelf-citationViswanathan, S. R., Ha, G., Hoff, A. M., Wala, J. A., Carrot-Zhang, J., Whelan, C. W., Haradhvala, N. J., Freeman, S. S., Reed, S. C., Rhoades, J., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.036 · Cited by 365 · cited 1×
“, 2015) or its enhancer (Takeda et al., 2018; Viswanathan et al., 2018) are frequently observed in metastatic castration-resistant prostate cancer (mCRPC).”
BackgroundSelf-citationTakeda, D. Y., Spisák, S., Seo, J.-H., Bell, C., O’Connor, E., Korthauer, K., Ribli, D., Csabai, I., Solymosi, N., Szállási, Z., et al. (2018) · Cell · doi:10.1016/j.cell.2018.05.037 · Cited by 317 · cited 1×
“, 2015) or its enhancer (Takeda et al., 2018; Viswanathan et al., 2018) are frequently observed in metastatic castration-resistant prostate cancer (mCRPC).”
BackgroundSelf-citationMouse Genome Database (MGD)-2018: knowledgebase for the laboratory mouse
Smith, C. L., Blake, J. A., Kadin, J. A., Richardson, J. E., Bult, C. J., & the Mouse Genome Database Group (2018) · Nucleic Acids Research · doi:10.1093/nar/gkx1006 · Cited by 219
Henzler, C., Li, Y., Yang, R., McBride, T., Ho, Y., Sprenger, C., Liu, G., Coleman, I., Lakely, B., Li, R., et al. (2016) · Nature Communications · doi:10.1038/ncomms13668 · Cited by 173 · cited 1×
“, 2016) and are observed in mCRPC (Henzler et al., 2016; Antonarakis, 2016).”
Background
Cited by
Biologically informed deep neural network for prostate cancer discovery
Elmarakeby, H. A., Hwang, J., Arafeh, R., Crowdis, J., Gang, S., Liu, D., AlDubayan, S. H., Salari, K., Kregel, S., Richter, C., et al. (2021) · Nature · doi:10.1038/s41586-021-03922-4 · Cited by 456
Self-citationTumor organoids: applications in cancer modeling and potentials in precision medicine
Xu, H., Jiao, D., Liu, A., & Wu, K. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01278-4 · Cited by 286
A Review of Gut Microbiota‐Derived Metabolites in Tumor Progression and Cancer Therapy
Yang, Q., Wang, B., Zheng, Q., Li, H., Meng, X., Zhou, F., & Zhang, L. (2023) · Advanced Science · doi:10.1002/advs.202207366 · Cited by 240
Hwang, J. H., Arafeh, R., Seo, J.-H., Baca, S. C., Ludwig, M., Arnoff, T. E., Sawyer, L., Richter, C., Tape, S., Bergom, H. E., et al. (2022) · eLife · doi:10.7554/elife.73223 · Cited by 26
Self-citation
Metadata
- Authors
- Hwang, J. H., Seo, J.-H., Beshiri, M. L., Wankowicz, S., Liu, D., Cheung, A., Li, J., Qiu, X., Hong, A. L., Botta, G., Golumb, L., Richter, C., So, J., Sandoval, G. J., Giacomelli, A. O., Ly, S. H., Han, C., Dai, C., Pakula, H., Sheahan, A., Piccioni, F., Gjoerup, O., Loda, M., Sowalsky, A. G., Ellis, L., Long, H., Root, D. E., Kelly, K., Van Allen, E. M., Freedman, M. L., Choudhury, A. D., & Hahn, W. C.
- Venue
- Cell Reports
- Publisher
- Elsevier BV
- Published
- 2019-11
- Volume
- 29
- Issue
- 8
- Pages
- 2355-2370.e6
- ISSN
- 2211-1247 (ISSN-L)
- OpenAlex
- W2991319487
- Cited by
- 70
- References
- 17
- FWCI
- 4.94
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.